INVIVYD, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INVIVYD, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $1.00K.
- INVIVYD, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $1.00K, a 0.00% change year-over-year.
- INVIVYD, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $1.00K.
- INVIVYD, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $1.00K.
- INVIVYD, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.00K, a 100.00% increase from fiscal 2022.
- INVIVYD, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-12-31 | $2.00K 10-K · filed 2025-03-20 | |
| 2023-06-30 | $1.00K 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $1.00K 10-K · filed 2024-03-28 | |
| 2022-03-31 | $1.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $5.00K 8-K · filed 2024-02-09 | |
| 2021-09-30 | $1.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $3.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |